NCT06441071 Patients' Positions on Analgesic Efficacy of ESPB
| NCT ID | NCT06441071 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Nanjing First Hospital, Nanjing Medical University |
| Condition | Erector Spinae Plane Block |
| Study Type | INTERVENTIONAL |
| Enrollment | 200 participants |
| Start Date | 2024-06-14 |
| Primary Completion | 2026-04-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 200 participants in total. It began in 2024-06-14 with a primary completion date of 2026-04-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to learn if patients remaining different positions for 30min after receiving ultrasound-guided erector spinae plane block influenced the postoperative analgesia. The main questions it aims to answer are: Does patients maintain prone position or lateral position for 30 min after ESPB provided superior analgesic effect than in the supine position? Is ESPB not inferior to PVB considering postoperative opioid consumption ? Researchers will compare the opioid consumption 24h postoperatively among the patients remaining supine, lateral, prone position after ESPB and PVB to see if patients maintaining lateral or prone position provided excellent postoperative analgesia. Participants will: Maintaining supine lateral or prone position for 30 min following ESPB or receiving PVB. Receiving postoperative NRS and QoR assessment
Eligibility Criteria
Inclusion Criteria: Patients undergoing Video-assisted Thoracoscopic Surgery under elective general anaesthesia were selected, regardless of sex, age 18-80 years, BMI: 18-30 kg.m-2, ASA classification I-III. Exclusion Criteria: 1. Allergy to the study drug or allergy to local anaesthetics; 2. History of opioid abuse; 3. Previous nerve block puncture with puncture site infection； 4. Peripheral neuropathy； 5. Coagulation abnormalities, defined as prothrombin time or partial activation time prothrombin time exceeding standard values or international normalised ratio (INR) ≥ 1.4, or platelet count ≤ 70 x 109 L-1.
Contact & Investigator
Tao Shan
STUDY DIRECTOR
Nanjing First Hospital, Nanjing Medical University
Frequently Asked Questions
Who can join the NCT06441071 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Erector Spinae Plane Block. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06441071 currently recruiting?
Yes, NCT06441071 is actively recruiting participants. Contact the research team at 1037031075@qq.com for enrollment information.
Where is the NCT06441071 trial being conducted?
This trial is being conducted at Nanjing, China.
Who is sponsoring the NCT06441071 clinical trial?
NCT06441071 is sponsored by Nanjing First Hospital, Nanjing Medical University. The principal investigator is Tao Shan at Nanjing First Hospital, Nanjing Medical University. The trial plans to enroll 200 participants.